Skip to main content
PMC home page
Drug Delivery logoLink to Drug Delivery
. 2018 Mar 15;25(1):773–779. doi: 10.1080/10717544.2018.1450909

Nasal delivery of H5N1 avian influenza vaccine formulated with GenJet™ or in vivo-jetPEI® induces enhanced serological, cellular and protective immune responses

Weiping Cao a,b,✉, Margarita Mishina a,b,c, Samuel Amoah a,b,c, Wadzanai P Mboko d, Caitlin Bohannon a,b,e, James McCoy f, Suresh K Mittal d, Shivaprakash Gangappa a,b, Suryaprakash Sambhara a,b
PMCID: PMC6058713  PMID: 29542358

Abstract

Avian influenza virus infection is a serious public health threat and preventive vaccination is the most cost-effective public health intervention strategy. Unfortunately, currently available unadjuvanted avian influenza vaccines are poorly immunogenic and alternative vaccine formulations and delivery strategies are in urgent need to reduce the high risk of avian influenza pandemics. Cationic polymers have been widely used as vectors for gene delivery in vitro and in vivo. In this study, we formulated H5N1 influenza vaccines with GenJet™ or in vivo-jetPEI®, and showed that these formulations significantly enhanced the immunogenicity of H5N1 vaccines and conferred protective immunity in a mouse model. Detailed analyses of adaptive immune responses revealed that both formulations induced mixed TH1/TH2 antigen-specific CD4 T-cell responses, antigen-specific cytotoxic CD8 T-cell and memory B-cell responses. Our findings suggest that cationic polymers merit future development as potential adjuvants for mucosal delivery of poorly immunogenic vaccines.

Keywords: Cationic polymers, H5N1 vaccine, adaptive immunity, protective immunity, mouse model, influenza

Introduction

Avian influenza viruses (AIVs) circulate naturally in wild aquatic birds and cause no illness in most cases. However, AIVs can infect domestic poultry, especially high pathogenic AIVs, and cause severe diseases with high mortality. Very rarely, human AIV infection occur through contact with infected animals or contaminated environments. Human infections with H5N1 viruses were first reported in Hong Kong in 1997 [Centers for Disease Control and Prevention (CDC), 1997]. As of April 2017, the H5N1 virus has spread to 18 countries resulting in 858 human infections with 53% mortality (World Health Organization, 2017). In recent years, H7N2, H7N9, H10N8, H6N1 and H5N6 viruses have crossed the species barrier to cause human infections (Gao et al., 2013; Shi et al., 2013; Zhang et al., 2014; Yang et al., 2015). Most AIVs caused sporadic and minor infections. However, novel mutations could potentially break the avian–human barrier and generate a serious pandemic; therefore, development of effective vaccines and exploration of new antiviral drugs are of urgent need. In 2007, a non-adjuvanted subvirion H5N1 avian influenza vaccine was approved by US Food and Drug Administration (FDA), but it requires two doses of 90 μg of hemagglutinin (HA), as compared to 15 μg of HA used for seasonal influenza vaccine. The two-dose regimen produced levels of antibodies expected to reduce the risk of H5N1 infection in 45% of people who received it (FDA, 2007). In 2013, an oil-in-water emulsion (AS03)-adjuvanted subviron H5N1 vaccine was approved in the US but only for stock-piling purpose (FDA, 2013). However, the continuing challenges including viral antigenic drift and shift, the high-dose vaccine requirement, the limited vaccine manufacturing capacity, and non-availability of proprietary adjuvants warrant developing novel formulations, adjuvants, and alternative delivery systems to improve the immunogenicity and protective efficacy of avian influenza vaccines.

Cationic polymers have been widely used as non-viral gene delivery vectors (Pack et al., 2005). The positive charge bearing cationic polymers interact with negative charged genetic material and form polyplexes spontaneously which protect the genes and mediate cellular entry (Pack et al., 2005). Cationic polymers have shown efficacy in DNA delivery as well as in sustained delivery of protein subunit vaccines (Adams et al., 2015). The cationic polymer polyethyleneimine (PEI) has been demonstrated as a potent mucosal adjuvant for viral glycoprotein antigens through promoting antigen uptake by dendritic cells (DCs) and subsequent DCs migration to draining lymph nodes (Wegmann et al., 2012). A recent study showed that avian H9N2 influenza whole inactivated virus plus PEI strongly enhanced mucosal and systemic antibody responses (Qin et al., 2015). GenJet™ and in vivo-jetPEI® are two commercially available and widely used transfection agents. In our study, we used the poorly immunogenic A/IN/05 vaccine as an antigen and demonstrated that both GenJet™ and in vivo-jetPEI® formulated H5N1 vaccine significantly enhance the protective immunity through the induction of mixed antigen-specific CD4 TH1/TH2 cells, antigen-specific cytotoxic CD8 cells, enhanced systemic antibody responses and memory B-cell responses.

Material and methods

Material

GenJet™ Plus DNA In Vivo Tranfection Reagent was purchased from SignaGen (Rockville, MD, USA) and in vivo-jetPEI® was purchased from Polyplus Transfection (New York, NY). H5N1 Monovalent Influenza Split Vaccine (A/Indonesia/05/2005, A/IN/05) was provided by GlaxoSmithKline Vaccines (Ste-Foy, Quebec, Canada). RG H5N1 A/IN/05 virus was made by reverse genetics with HA and NA from A/IN/05 virus and the remaining six gene segments from A/Puerto Rico/8/1934 (PR8) virus. Viruses were propagated in 10-day-old embryonated chicken eggs for 48 h. Pooled allantoic fluids were clarified by centrifugation, aliquoted, and stored at –80 °C until use.

Immunization and virus challenge

Six- to eight-week-old female BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were immunized (five animals/group) by the intranasal (i.n.) route with 3 µg of A/IN/05 vaccine with or without GenJet™ (10 µl/each mouse as described earlier (Kulkarni et al., 2014)) or in vivo-jetPEI® (0.6 μl/mouse according to manufacturer’s protocol). Control mice were immunized with GenJet™ alone, in vivo-jetPEI® alone, or with PBS. Four weeks later, mice were boosted with the same immunization regimen. Sera were obtained three weeks post-primary and post-boost to determine antibody responses. Four weeks post-boost, mice were challenged with 5 × LD50 of RG A/IN/05 virus and monitored for weight loss and survival for 16 days. Animal research was conducted under the guidance of the CDC’s Institutional Animal Care and Use Committee in an Association for Assessment and Accreditation of Laboratory Animal Care International-accredited animal facility. Mice that lost >25% of their pre-infection body weight were euthanized.

ELISA

Nunc 96-well plates (Maxi-Sorb) were coated with 5 µg/ml HA of monovalent A/IN/05 vaccine in PBS at 4 °C overnight. The plates were then washed and blocked with 4% BSA in PBS-Tween (PBS-T) (0.05%) at room temperature (RT) for 1 h. Dilutions of sera were added onto the plate at RT for 2 h. After washing the plates, the HRP anti-mouse antibodies specific for IgA, IgG, IgM, IgG1, IG2a, IgG2b, or IgG3 (Southern Biotech, Birmingham, AL) were added onto the plate at RT for 1 h. The wells were developed with TMB peroxidase substrate (eBioscience, San diego, CA, USA) after washing and the absorbance was measured at 450 nm using a BioTek Plate Reader (BioTek, Winooski, VT, USA).

ELISPOT assay

The frequency of virus-specific antibody-secreting cells (ASCs) in the spleen was detected by an ELISPOT assay. Briefly, 106 cells were added onto antigen-coated plates and incubated overnight at 37 °C in a humidified atmosphere with 5% CO2. The plates were incubated with biotinylated anti-mouse IgG (Southern Biotech) followed by alkaline phosphatase-conjugated streptavidin and developed with Vector Blue Alkaline Phosphatase Substrate Kit III (Vector Laboratories, Burlingame, CA). Spot forming units were counted using ImmunoSpot® (Cellular Technology Ltd., Shaker Heights, OH) and expressed as a percentage of antigen-specific IgG secreting B cells out of the total IgG-secreting B cells.

Cell-mediated immune responses

Single cell suspensions were prepared from the lungs, draining lymph nodes and spleen tissues collected 1 week after the booster immunization. Activated T cells in the lung were identified using anti-CD44 antibody. HA-specific CD8+ T cells in the lungs, lymph nodes and spleens were identified using H-2Kd/IYSTVASSL tetramer (NIH Tetramer Core Facility, Emory University, Atlanta, GA, USA). To detect intracellular cytokine production by CD4 or CD8 T cells, 106 cells from the spleen were stimulated in vitro with RG A/IN/05 virus at an MOI of 1 for 16 h or with HA peptide (1 µM, NeoBiolab, Woburn, MA, USA) for 6 h, respectively. GolgiPlug™ (BD Bioscience, San Jose, CA, USA) was added during the last 5 h of incubation. Cells were surface stained with either anti-CD4 or anti-CD8 antibody (BD Bioscience), followed by intracellular staining with anti-IFN-γ antibody (BD Bioscience). Samples were analyzed using an LSRII Flow cytometer (BD Biosciences), and the cytometric data were analyzed using FlowJo software version 9.3.3 (Tree Star, Inc., Ashland, OR, USA).

Hemagglutination inhibition assay

Sera collected from control and immunized mice were treated with receptor-destroying enzyme (RDE, Denka Seiken, Japan) at 37 °C overnight and tested against RG A/IN/05 virus by the standard hemagglutination inhibition (HI) assay with 1% horse red blood cells (RBCs). Briefly, 25 µl of 1× PBS was added to wells of a 96-well V-bottom plate (Corning, NY, USA). This was followed by adding 50 µl of RDE-treated sera to each column, which was then serially diluted. Of 4 HA units of RG A/IN/05 virus, 25 µl was added to each well and incubated at RT for 60 min. Finally, 50 µl of 1% standardized horse RBCs in PBS was added to each well and incubated at RT for exactly 60 min. The reciprocal serial dilutions of the sera that showed complete inhibition of hemagglutination were recorded as the HI titer.

Statistical analysis

Statistical analyses were performed using GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA, USA). Groups were compared by one-way analysis of variance (ANOVA) followed by Bonferroni multiple comparison test. The Mann–Whitney U-test was used to determine significance of antibody (HI) titers. The log-rank (Mantel–Cox) test was used to compare percent survival among groups of mice. Data were presented as mean ± standard error of mean (SEM). All differences were considered statistically significant when the p value was ≤.05.

Results

GenJet™ and in vivo-jetPEI® enhanced the H5N1 vaccine-induced antibody responses and memory B-cell responses

Vaccines for protection against influenza virus infections should induce an optimal systemic antibody response. To quantitate the antibody responses, mice were immunized intranasally with a H5N1 monovalent vaccine including 3 µg of HA with or without cationic polymers (GenJet™ or in vivo-jetPEI®). Sera were collected at three weeks post-booster immunization to measure the antigen-specific IgG, IgM and IgA production by ELISA. Control mice were immunized with the formulations alone or PBS without antigen. As shown in Figure 1(A), sera from mice immunized with formulations only or PBS have no detectable levels of antibody responses. The H5N1 vaccine group also did not induce significant antibody responses, though one mouse had slightly elevated IgG and IgA production. However, when formulated with GenJet™ or in vivo-jetPEI®, H5N1 vaccine induced significantly higher IgG, IgA and IgM production in the sera as compared to the controls. We next examined the memory B-cell response in the spleen upon booster immunization by measuring the frequency of H5N1-specific ASCs by an ELISPOT assay. The frequency of H5N1-specific IgG ASCs in the spleens of mice immunized with formulations alone or PBS are low or undetectable (Figure 1(B)). Immunization with H5N1 vaccine alone did not increase the frequency of ASCs, while the addition of either GenJet™ (p < .01) or in vivo-jetPEI® (p < .05) to the vaccine significantly increased the frequency of IgG-secreting cells in the spleen. In summary, these data suggest that intranasal administration of H5N1 vaccine formulated with GenJet™ or in vivo-jetPEI® enhanced the serum antibody responses and memory B-cell responses in the spleen.

Figure 1.

Figure 1.

Open in a new tab

GenJet™ and in vivo-jetPEI enhances the H5N1 vaccine-induced systemic antibody responses and memory B-cell responses. Balb/c mice (5 mice/group) were intranasally administered with 3 µg of A/IN/05 vaccine with or without GenJet™ (10 µl/each mouse as described in previous study (Kulkarni et al., 2014)) or in vivo-jetPEI® (0.6 μl/mouse according to manufacturer’s protocol). One month later, mice were boosted with the same vaccine formulations. The control mouse group received GenJet™, in vivo-jetPEI® or PBS at both time points. (A) Three weeks after booster immunization, sera were collected and IgG, IgA and IgM antibodies against A/IN/05 were assessed by ELISA. (B) One week after booster immunization, the spleen were harvested and the frequency of A/IN/05-specific IgG+ ASCs in the spleen were measured by ELISPOT assay. The number of A/IN/05-specific IgG+ ASCs were normalized against the number of total IgG+ secreting ASCs and presented as % Ag-specific IgG+ B cells. The data are representative of two independent experiments (3–5 mice each group) and error bars represent SEM. One-way ANOVA with Bonferroni post-analysis was used to analyze differences among different groups. p < .05, p < .01 and p < .001 as compared to the H5N1 vaccine alone group.

GenJet™ and in vivo-jetPEI® enhanced the H5N1-specific T-cell responses

Optimal antibody responses against influenza virus infection require the help from T-cell immune responses. T-cell activation is initiated in the draining lymph nodes after resident DCs in lungs capture antigen and present processed antigens to the antigen-specific T cells in the lymph nodes. Activated T cells then migrate to sites of infection to execute their effector functions. IFN-γ is one of the most important cytokines produced by effector T cells. The activation of vaccine-specific CD4 and CD8 T cells in the lung was examined in mice immunized with H5N1 vaccine with or without formulations using prime-boost regimen. Lung tissues were harvested 1 week post-booster immunization and IFN-γ production by activated T cells in the lung was measured by intracellular cytokine staining. H5N1 vaccine alone did not increase the IFN-γ production in activated CD4 and CD8 T-cell subsets. H5N1 vaccine with formulations slightly increased the IFN-γ production among CD8 T cells, but the change did not reach statistical significance (Figure 2(A) and Supplementary Figure S1). However, co-administration vaccine with GenJet™ or in vivo-jetPEI® significantly increased IFN-γ production by activated CD4 T cells (Figure 2(A) and Supplementary Figure S1).

Figure 2.

Figure 2.

Open in a new tab

GenJet™ and in vivo-jetPEI® enhanced the H5N1-specific T-cell responses. Balb/c mice (3–5 mice/group) were intranasally administered with A/IN/05 vaccine with or without GenJet™ or in vivo-jetPEI® using prime-boost regimen as described in Figure 1. (A) One week after booster immunization, the lung tissues were harvested and single cell suspensions were prepared. About 106 cells from the lung were stimulated in vitro with HA peptide for 6 h to examine the antigen-specific CD8 T-cell response; or with RG A/IN/05 virus at an MOI of 1 for 16 h to examine the antigen-specific CD4 T-cell response. GolgiPlug™ was added during the last 5 h of incubation. Cells were surface stained with anti-CD44, anti-CD4 or anti-CD8 antibody (BD Bioscience), followed by intracellular staining with anti-IFNγ antibody (BD Bioscience). The frequency of IFN-γ producing T cells in total activated T cells was presented. (B) One-week post-booster immunization, the draining lymph nodes, lungs and spleen tissues were harvested and the frequency of HA518-specific CD8 T cells in total activated CD8 T cells was stained using H-2Kd/IYSTVASSL tetramer. (C) Three weeks after booster immunization, sera were collected and IgG2a, IgG2b IgG3 and IgG1 antibodies against A/IN/05 were assessed by ELISA. The data are representative of two independent experiments (3–5 mice each group) and error bars represent SEM. One-way ANOVA with Bonferroni post-analysis was used to analyze differences among treatments. p < .05, p < .01 and p < .001 as compared to the H5N1 vaccine alone group.

Virus-specific cytotoxic CD8 T cells play a central role in the immune responses by eliminating virus infected cells. In response to H5N1 vaccination, antigen-specific CD8 T cells from the draining lymph nodes, spleens, and sites of infection (lungs) can be identified with the H-2Kd/IYSTVASSL (HA518) tetramer. As shown in Figure 2(B), in mice immunized with H5N1 vaccine alone, the frequencies of HA518-specific CD8 T cells were very low in the lymph node and almost undetectable in the lung and spleen tissues. In contrast, GenJet™ or in vivo-jetPEI®-formulated-H5N1 vaccine remarkably increased the frequencies of HA518-specific CD8 T cells ∼1.5–10-fold in all tissues examined.

Virus-activated CD4 T cells can mature into distinct TH cell types such as TH1, TH2 and TH17 (Hirahara and Nakayama, 2016). TH1 or TH2 subsets drive differential B-cell responses to secrete distinct immunoglobulin isotypes (Mosmann et al., 1986; Abbas et al., 1996; Mosmann and Sad, 1996). The isotypes of serum H5N1-binding antibodies from mice immunized with H5N1 vaccine with or without formulations were measured by ELISA. H5N1 vaccine alone elicited more IgG1 production than IgG2a, IgG2b and IgG3 as shown in Figure 2(C). However, GenJet™ and in vivo-jetPEI® adjuvantation induced a mixed IgG1, IgG2a, IgG2b and IgG3 responses (Figure 2(C)). Therefore, these formulations significantly enhanced both the antigen-specific CD8 responses as well as CD4 T cell activation with mixed TH1 and TH2 responses.

GenJet™ and in vivo-jetPEI® enhanced the protective immunity

To investigate whether nasal administration of GenJet™ or in vivo-jetPEI® could enhance the protective efficacy of an H5N1 vaccine, the production of sera virus-neutralizing antibody was measured by HI assay. Mice were immunized with a prime-boost regimen 4 weeks apart. Sera samples were collected at 3 weeks following primary immunization (week 3 sera) and booster immunization (week 7 sera). HI titers against RG A/IN/05 viruses were measured. Mice immunized with H5N1 vaccine alone did not induce detectable HI titers after primary vaccination (Figure 3(A)). However, mice immunized with GenJet™ or in vivo-jetPEI®-adjuvanted H5N1 vaccine developed low levels of HI titers even after a single immunization. Six out of seven mice immunized with GenJet™-formulated H5N1 vaccine showed an HI titer of 40, indicative of a protective response (Figure 3(A)). Three weeks post-booster immunization, only one mouse immunized with H5N1 vaccine alone had an HI titer of 40. However, all mice immunized with vaccine and formulations developed significantly higher HI titers (Figure 3(A)). These results suggest that GenJet™ and in vivo-jetPEI® significantly enhanced the immunogenicity of H5N1 vaccine.

Figure 3.

Figure 3.

Open in a new tab

GenJet™ and in vivo-jetPEI enhanced the protective immunity. Balb/c mice (5 mice/group) were intranasally administered with A/IN/05 vaccine with or without GenJet™ or in vivo-jetPEI® using the prime-boost regimen as described in Figure 1. (A) Sera were collected at the third week following primary immunization (W3) and booster immunization (W7). HI titers were measured against RG A/IN/05 virus. (b,c) Four weeks following booster immunization, mice were challenged with 5 × LD50 of RG A/IN/05 virus. Mice were weighed every day to monitor body weight changes (B) and mortality (C). Mice that lost more than 25% body weight were euthanized and scored as a fatality. One-way ANOVA with Bonferroni post-analysis was used to compare the percentage of body weight changes and the log-rank (Mantel–Cox) test was used to compare percent survival among groups of mice. n = 5 mice for each group from two independent experiments and the error bars represent SEM. p < .05, p < .01 and p < .001 as compared to the H5N1 vaccine alone group.

To further examine the protective efficacy of H5N1 vaccine, mice immunized with H5N1 vaccine formulated with or without GenJet™ or in vivo-jetPEI® were challenged with a homologous RG A/IN/05 virus 4 weeks post-boost. All mice immunized with formulations alone or PBS showed significant body weight loss (Figure 3(B)) and succumbed to infection between Day 7 and 8 post-challenge (Figure 3(C)). Only one mouse out of four that received H5N1 vaccine alone survived the virus challenge, but showed significant weight loss (Figure 3(B,C)). In contrast, all mice immunized with the vaccine formulated with GenJet™ or in vivo-jetPEI® survived challenge and no significant body weight loss was observed (Figure 3(B,C)). Therefore, both GenJet™ or in vivo-jetPEI® significantly enhanced the protective efficacy of H5N1 vaccine.

Discussion

The spread of highly pathogenic AIV in birds and domestic poultry, the emergence of novel virus strains, and the increasing number of their direct transmission to humans have raised significant concern about the avian influenza pandemic threat (Poovorawan et al., 2013). Vaccination to prevent infection is no doubt the most cost-effective public health strategy. Unfortunately, the current avian influenza vaccines are poorly immunogenic even with high dose or alternative immunization route as shown in animal studies and human clinical trials (FDA, 2007; Layton et al., 2011a, 2011b; Cao et al., 2016; Jones et al., 2017). The manufacturing capacity is also limited to produce enough vaccine in a pandemic situation. Adjuvants have been shown to provide great advantages in enhancing the immunogenicity of vaccine, such as dose sparing, increased vaccine efficacy in elder and immunocompromised populations, and a broader protective immunity (Reed et al., 2013). Aluminum salts are the most commonly used adjuvants in human vaccines (Reed et al., 2013). In recent years, influenza vaccines formulated with two squalene-based oil-in-water emulsions have been approved for use in human in the US and Europe for seasonal and pandemic influenza (FDA, 2015). Although both adjuvants hold great promise for enhancing the immunogenicity of vaccine, AS03 has been associated with narcolepsy (Ahmed et al., 2014) and these are proprietary adjuvants. Therefore, challenges remain for developing new adjuvants and alternative delivery systems for avian influenza vaccine.

Cationic polymers have gained tremendous attention in recent years as non-viral vectors in gene and protein delivery (Guy et al., 2001; Sanchez et al., 2001). PEI is the most widely used cationic polymer due to its strong DNA compaction capacity with an intrinsic endosomolytic activity (Di Gioia and Conese, 2009). The adjuvanticity of PEI has been demonstrated initially with viral subunit soluble glycoprotein antigens by Wegmann et al. (2012). The potency of gene delivery to the lung tissue by PEI (Di Gioia and Conese, 2009) and its adjuvanticity for H9N2 influenza whole inactivated virus in mouse model have been shown in earlier studies as well (Qin et al., 2015). Consistent with these findings, our data indicated that two efficient transfection reagents, GenJet™ and in vivo-jetPEI®, significantly increased serum antibody (IgG, IgA and IgM) responses when administerred together with H5N1 vaccine. The development of B cell memory is the key for rapid antibody production in response to the same pathogen. Shortly after immunization, antibody-secreting plasmablasts are highly abundant in the spleen (Giesecke et al., 2014). Our study further demonstrated that, one week post-booster immunization, the mouse group that received vaccine formulated with GenJet™ or in vivo-jetPEI® displayed significantly higher frequency of IgG ASCs in the spleen. However, no detectable antigen-specific IgG antibody producing cells were observed in the spleens of mice immunized with the H5N1 vaccine alone. Therefore, both GenJet™ and in vivo-jetPEI® induced enhanced systemic antibody responses and the number of antibody-secreting B cells found in the spleen following intranasal immunization.

Effective antibody response is essential to prevent influenza virus infection by blocking virus entry, but the optimal antibody response and ultimate elimination of the virus-infected cells require effector CD4 and CD8 T cells. Qin et al. (2015) showed that the activation and proliferation of total CD4 and CD8 T cells were increased by vaccination with H9N2 vaccine formulated with PEI (Qin et al., 2015). Our study further characterized the antigen-specific T cell response in mice immunized with H5N1 vaccine with or without GenJet™ or in vivo-jetPEI®. Both formulations substantially increased the frequency of antigen-specific cytotoxic CD8 T cells in the draining lymph nodes where T-cell activation was initiated. Activated T cells migrate from LN to the lungs where they eliminate virus-infected cells. After clearance, immunological memory is established both locally and systemically. The ability of CD8 T cells to recognize conserved viral genes is critical in conferring heterosubtypic immunity (Sridhar, 2016). In addition to the increased frequency of antigen-specific CD8 T cells, IFN-γ production by CD8 T cells was also slightly increased in the spleens of mice immunized with the formulated vaccine. Similar to CD8 T cells, the frequency of IFN-γ producing CD4 T cells were increased in mice that received the H5N1 vaccine formulated with GenJet™ or in vivo-jetPEI®. CD4 T-cell induction is required for the generation of protective antibody responses by B cell and expansion of antiviral CTL responses (Leist et al., 1987; Matloubian et al., 1994). Serum IgG isotype profiles were further characterized and the results showed that vaccine alone elicited more IgG1 (TH2 type response) production than IgG2a, IgG2b and IgG3 (TH1 type response), whereas the H5N1 vaccine formulated with GenJet™ or in vivo-jetPEI® induced a mixed TH1 and TH2 response. Wegmann et al. (2012) and Qin et al. (2015) both demonstrated that PEI-adjuvanted vaccines enhanced the innate responses including antigen uptake, DC migration, and maturation which subsequently increased the humoral and cellular immune responses.

Hemagglutinin (HA) is the major surface protein of the influenza A virus which mediates virus binding and entry into cells. Therefore, the induction of antibody responses to HA are crucial. In the presence of GenJet™ or in vivo-jetPEI®, the H5N1 vaccine induced significantly higher HI titers even after single immunization while the vaccine alone failed to induce any detectable levels of HI titers. Upon booster immunization, only one out of four mice that received vaccine alone showed a HI titer above 40. However, all mice that received the vaccine formulated with GenJet™ or in vivo-jetPEI® displayed 100–300-fold higher HI titers and subsequently were completely protected from homologous virus challenge.

In summary, GenJet™ and in vivo-jetPEI® formulated H5N1 vaccine elicited significantly higher serum antibody responses and antigen-specific T- and B-cell responses. The neutralizing antibody responses against HA were also significantly increased in mice immunized with the vaccine plus formulations as compared to the vaccine alone groups. These enhanced immune responses culminated in enhanced protection against challenge with a homologous H5N1 virus. Both GenJet™ and in vivo-jetPEI® have potential applications as adjuvants for poorly immunogenic influenza vaccines for nasal delivery to prepare for a H5N1 pandemic.

Supplementary Material

IDRD_Cao_et_al_Supplemental_Content.pdf
IDRD_A_1450909_SM1313.pdf (186.7KB, pdf)

Funding Statement

This work was supported by the Influenza Division, Centers for Disease Control and Prevention, and by the Public Health Service grant [AI059374] from the National Institute of Allergy and Infectious Diseases.

Acknowledgements

We thank NIH Tetramer Core Facility at Emory University for providing reagents for this study.

Disclosure statement

No potential conflict of interest was reported by the authors. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the funding agencies.

References

  1. Abbas AK, Murphy KM, Sher A. (1996). Functional diversity of helper T lymphocytes. Nature 383:787–93. [DOI] [PubMed] [Google Scholar]
  2. Adams JR, Haughney SL, Mallapragada SK. (2015). Effective polymer adjuvants for sustained delivery of protein subunit vaccines. Acta Biomater 14:104–14. [DOI] [PubMed] [Google Scholar]
  3. Ahmed SS, Schur PH, MacDonald NE, Steinman L. (2014). Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun 50:1–11. [DOI] [PubMed] [Google Scholar]
  4. Cao W, Davis WG, Kim JH, et al. (2016). An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice. Nanomedicine 12:1909–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Centers for Disease Control and Prevention (CDC) (1997). Isolation of avian influenza A(H5N1) viruses from humans–Hong Kong, May-December 1997. MMWR Morb Mortal Wkly Rep 46:1204–7. [PubMed] [Google Scholar]
  6. Di Gioia S, Conese M. (2009). Polyethylenimine-mediated gene delivery to the lung and therapeutic applications. Drug Des Devel Ther 2:163–88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. FDA (2007). FDA approval letter - influenza virus vaccine, H5N1. Rockville, MD, 2007 [April 17]. Available at: https://www.drugs.com/newdrugs/fda-approves-first-u-s-vaccine-humans-against-avian-influenza-virus-h5n1-442.html [last accessed 28 Feb 2018]. [Google Scholar]
  8. FDA (2013). FDA approval letter - influenza A (H5N1) virus monovalent vaccine, adjuvanted. 2013 [Nov 22]. Available at: https://www.drugs.com/newdrugs/fda-approves-first-adjuvanted-vaccine-prevention-h5n1-avian-influenza-3972.html [last accessed 28 Feb 2018.]. [Google Scholar]
  9. FDA (2015). FDA approves first seasonal influenza vaccine containing an adjuvant. Available at: https://www.medscape.com/viewarticle/855000 [last accessed 28 Feb 2018.]. [Google Scholar]
  10. Gao R, Cao B, Hu Y, et al. (2013). Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368:1888–97. [DOI] [PubMed] [Google Scholar]
  11. Giesecke C, Frolich D, Reiter K, et al. (2014). Tissue distribution and dependence of responsiveness of human antigen-specific memory B cells. J Immunol 192:3091–100. [DOI] [PubMed] [Google Scholar]
  12. Guy B, Pascal N, Francon A, et al. (2001). Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 19:1794–805. [DOI] [PubMed] [Google Scholar]
  13. Hirahara K, Nakayama T. (2016). CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Intimm 28:163–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jones EN, Amoah S, Cao W, et al. (2017). An adjuvanted A(H5N1) subvirion vaccine elicits virus-specific antibody response and improves protection against lethal influenza viral challenge in mouse model of protein energy malnutrition. J Infect Dis 216(Suppl. 4):S560–S5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kulkarni RR, Rasheed MA, Bhaumik SK, et al. (2014). Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. J Virol 88:13990–4001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Layton RC, Gigliotti A, Armijo P, et al. (2011a). Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret. PLoS One 6:e20641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Layton RC, Petrovsky N, Gigliotti AP, et al. (2011b). Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 29:6242–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Leist TP, Cobbold SP, Waldmann H, et al. (1987). Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol 138:2278–81. [PubMed] [Google Scholar]
  19. Matloubian M, Concepcion RJ, Ahmed R. (1994). CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 68:8056–63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mosmann TR, Cherwinski H, Bond MW, et al. (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–57. [PubMed] [Google Scholar]
  21. Mosmann TR, Sad S. (1996). The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17:138–46. [DOI] [PubMed] [Google Scholar]
  22. Pack DW, Hoffman AS, Pun S, Stayton PS. (2005). Design and development of polymers for gene delivery. Nat Rev Drug Discov 4:581–93. [DOI] [PubMed] [Google Scholar]
  23. Poovorawan Y, Pyungporn S, Prachayangprecha S, Makkoch J. (2013). Global alert to avian influenza virus infection: from H5N1 to H7N9. Pathog Glob Health 107:217–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Qin T, Yin Y, Huang L, et al. (2015). H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice. Clin Vaccine Immunol 22:421–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Reed SG, Orr MT, Fox CB. (2013). Key roles of adjuvants in modern vaccines. Nat Med 19:1597–608. [DOI] [PubMed] [Google Scholar]
  26. Sanchez V, Gimenez S, Haensler J, et al. (2001). Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones. FEMS Immunol Med Microbiol 30:157–65. [DOI] [PubMed] [Google Scholar]
  27. Shi W, Shi Y, Wu Y, et al. (2013). Origin and molecular characterization of the human-infecting H6N1 influenza virus in Taiwan. Protein Cell 4:846–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sridhar S. (2016). Heterosubtypic T-cell immunity to influenza in humans: challenges for universal T-cell influenza vaccines. Front Immunol 7:195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Wegmann F, Gartlan KH, Harandi AM, et al. (2012). Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat Biotechnol 30:883–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. World Health Organization (2017). Influenza: cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. Available at: http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/ [last accessed 01 Dec 2017]. [Google Scholar]
  31. Yang ZF, Mok CK, Peiris JS, Zhong NS. (2015). Human infection with a novel avian influenza A(H5N6) virus. N Engl J Med 373:487–9. [DOI] [PubMed] [Google Scholar]
  32. Zhang T, Bi Y, Tian H, et al. (2014). Human infection with influenza virus A(H10N8) from live poultry markets, China, 2014. Emerg Infect Dis 20:2076–9. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

IDRD_Cao_et_al_Supplemental_Content.pdf
IDRD_A_1450909_SM1313.pdf (186.7KB, pdf)

Articles from Drug Delivery are provided here courtesy of Taylor & Francis

RESOURCES